Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Lessons from Jack Griffin and the "pathogenesis of peripheral nerve disease".
Tysabri
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
High-field imaging of neurodegenerative diseases.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
The environment and disease: association or causation?
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Microvesicles: novel biomarkers for neurological disorders.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.

Pages